Meningococcal Immunization, Healthy Volunteers
Conditions
Brief summary
This study is the first study of Sanofi's Pentavalent Meningococcal ABCYW vaccine clinical development program to be conducted in the pediatric population below 10 years of age. The aim of the study is to assess 2 formulations of the MenPenta vaccine compared to licensed meningococcal vaccines when administered alone in children (Stage 1) or concomitantly with routine pediatric vaccines in toddlers (Stage 2) and infants (Stage 3). Study details include: The study duration per participant will be up to 12 months for children in Stage 1 and toddlers in Stage 2 and 16 to-19 months for infants in Stage 3.
Interventions
BIOLOGICALPentavalent Meningococcal ABCYW vaccine
Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)
BIOLOGICALMenACYW conjugate vaccine
Pharmaceutical form: Solution for injection in vial Route of administration: Intramuscular (IM)
BIOLOGICALMeningococcal group B vaccine
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
DRUGParacetamol
Pharmaceutical form:Suspension-Route of administration:oral
BIOLOGICALDTap-HepB-IPV-Hib vaccine
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
BIOLOGICALRotavirus vaccine
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
BIOLOGICALPneumococcal 13-valent conjugate vaccine
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
Sponsors
Sanofi Pasteur, a Sanofi Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Partially blinded (treatment assignment is blinded between the two investigational formulation groups, and open label between the investigation and the comparator group) * Laboratory personnel will be blinded to the treatment assignment * Participants, Investigators, and Site staff preparing and administering the study intervention will be unblinded between the MenPenta and comparator groups but will be blinded between the 2 MenPenta groups The Sponsor will be partially blinded. At the time of periodic data reviews, additional measures are put in place to maintain the blind of the study participants for the Sponsor staff. The data review will be conducted on the basis of blinded outputs (where data of the 2 MenPenta groups and the control group will be reviewed in aggregate, without any distinction by group). By design, the Sponsor team will have access to partially blinded data for individual participants (eg, for assessment of SAE)
Eligibility
Sex/Gender
ALL
Age
56 Days to 9 Years
Healthy volunteers
Yes
Inclusion criteria
* Aged 2 to 9 years (Stage 1) or 12 to 15 months (Stage 2) or 56 to 89 days (Stage 3) on the day of inclusion * For infants and toddlers, born at full term of pregnancy (≥37 weeks) and with a birth weight ≥ 2.5 Kg or born after a gestation period of period above 28 (\> 28 weeks) through 36 weeks with a birth weight ≥ 1.5 Kg and in both cases medically stable as assessed by the investigator, based on the following definition: "Medically stable" refers to the condition of premature infants who do not require significant medical support or ongoing management for debilitating disease and who have demonstrated a clinical course of sustained recovery by the time they receive the first dose of study intervention * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and judgement of the investigator
Exclusion criteria
Participants are excluded from the study if any of the following criteria apply: * Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months or since birth for infants; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months or since birth for and infants) * History of any meningitis infection, confirmed either clinically, serologically, or microbiologically * At high risk of meningococcal infection during the study * Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances * Individual with active tuberculosis * History of Guillain-Barré syndrome * For Stage 3 infants: History of intussusception * Previous vaccination against meningococcal serogroups A, B, C, W, and/or Y with an investigational or marketed vaccine * For Stage 3 infants: receipt of the first dose of rotavirus vaccine less than 28 days before the first trial vaccination NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with unsolicited immediate adverse events (AEs) | Within 30 minutes after each vaccination | Unsolicited systemic AEs that occur within 30 minutes after vaccination |
| Number of participants with solicited injection site reactions or systemic reactions | Within 7 days after each vaccination | Pre-defined solicited injection site reactions and systemic reactions that are pre-listed in the diary cards and CRF |
| Number of participants with unsolicited AEs | Within 30 days after each vaccination | Unsolicited AEs other than solicited reactions |
| Number of participants with serious adverse events (SAEs) | Throughout the study, from first visit until 180 days after the last vaccination | SAEs (including adverse events of special interest \[AESIs\]) reported throughout the study |
| hSBA meningococcal serogroups A, C, W, and Y antibody titers pre-dose and 30 days after the second and third dose in infant participants | For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391 | hSBA titers ≥ 1:8 post-vaccination (post-second and third dose) |
| hSBA meningococcal serogroups A, C, W, and Y vaccine seroresponse pre-dose and 1 month after the second and third dose in infant participants | For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391 | Seroresponse defined as post-vaccination titers ≥ 1:16 for participants with pre-vaccination hSBA titers \< 1:4 or or postvaccination titers ≥ 4 times the lower limit of quantification (LLOQ) for participants with a pre-vaccination titer ≤ LLOQ or a post-vaccination titer ≥ 4 times the pre-vaccination titer for participants with a pre-vaccination titer ≥ LLOQ |
| Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroups A, C, W and Y pre-dose and 1 month after the second and third dose in infant participants | For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391 | Geometric mean titers (pre-dose and post-second and third dose) |
| Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each of serogroups A, C, W, and Y pre-dose and 1 month after the second and third dose in infant participants | For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391 | — |
| Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:4 pre-dose and 1 month after second dose of vaccination against serogroup B, before and 30 days after third dose in infants | For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391 | hSBA titers ≥ 1:4 for reference MenB strains |
| Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:8 pre-dose and 1 month after the second dose of vaccination against serogroup B, before and 30 days after third dose in infants | For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391 | hSBA titers ≥ 1:8 for reference MenB strains |
| hSBA meningococcal serogroup B seroresponse pre-dose and 1 month after the second dose of vaccination against serogroup B, before and 30 days after third dose in infant participants | For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391 | Seroresponse defined as a 4-fold increase in hSBA titers |
| Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroup B (reference MenB strains) pre-dose and 1 month after the second dose of vaccination against serogroup B, before and 30 days after third dose in infant participants | Day 01, Day 91, Day 181 and Day 211 (for Stage 3) | Geometric mean titers (pre-dose and post-second dose) for the reference MenB strains |
| Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each and all of serogroup B (ref. MenB strains) predose and 1 month after 2nd dose against serogroup B, before and 30 days after 3rd dose in infants | For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391 | — |
| Percentage of participants with hSBA titers less than LLOQ against all serogroup B (ref. MenB strains) pre-dose and 1 month after the 2nd dose of vaccination against serogroup B, before and 30 days after 3rd dose in infants | For Stage 3: Day 1, Day 91, Day 301-361, Day 331-391 | — |
| hSBA meningococcal serogroups A, C, W, and Y antibody titers in children and toddlers | For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211 | hSBA titers ≥ 1:8 for serogroups A, C, W, and Y |
| hSBA meningococcal serogroups A, C, W, and Y vaccine seroresponse in children and toddlers | For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211 | Seroresponse defined as post-vaccination titers ≥ 1:16 for participants with pre-vaccination hSBA titers \< 1:4 or or postvaccination titers ≥ 4 times the lower limit of quantification (LLOQ) for participants with a pre-vaccination titer ≤ LLOQ or a post-vaccination titer ≥ 4 times the pre-vaccination titer for participants with a pre-vaccination titer ≥ LLOQ |
| Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroups A, C, W and Y pre-dose and 1 month after the second dose children and toddlers | For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211 | — |
| Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each of serogroups A, C, W, and Y children and toddlers | For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211 | — |
| Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:4 in children and toddlers | For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211 | — |
| Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:8 in children and toddlers | For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211 | — |
| hSBA meningococcal serogroup B (reference MenB strains) vaccine seroresponse in children and toddlers | For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211 | Seroresponse defined as a 4-fold increase in hSBA titers |
| Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroup B (reference MenB strains) in children and toddlers | For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211 | — |
| Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each and all of serogroup B (reference MenB strains) in children and toddlers | For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211 | — |
| Percentage of participants with hSBA titers less than the lower limit of quantification (LLOQ) against all serogroup B (reference MenB strains) in children and toddlers | For Stage 1 and 2: Day 1, Day 31, Day 181, Day 211 | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| hSBA meningococcal serogroup B (additional MenB strains) vaccine seroresponse in children, toddler and infant participants | Stage 1 and 2: Day 1 and Day 211. Stage 3: Day 1, Day 331-391 | — |
| Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (additional MenB strains) ≥ 1:4 in children, toddler and infant participants | Stage 1 and 2: Day 1 and Day 211. Stage 3: Day 1, Day 331-391 | hSBA titers ≥ 1:4 for additional MenB strains |
| Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (additional MenB strains) ≥ 1:8 in children, toddler and infant participants | Stage 1 and 2: Day 1 and Day 211. Stage 3: Day 1, Day 331-391 | hSBA titers ≥ 1:8 for additional MenB strains |
| Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroup B (additional MenB strains) in children, toddler and infant participants | Stage 1 and 2: Day 1 and Day 211. Stage 3: Day 1, Day 331-391 | — |
| Percentage of participants with hSBA composite seroresponse titers more or equal to LLOQ each and all additional MenB strains in children, toddler and infant participants | Stage 1 and 2: Day 1 and Day 211. Stage 3: Day 1, Day 331-391 | — |
| Percentage of participants with hSBA composite seroresponse titers less than LLOQ all additional MenB strains in children, toddler and infant participants | Stage 1 and 2: Day 1 and Day 211. Stage 3: Day 1, Day 331-391 | — |
Countries
Brazil, Czechia, Denmark, Finland, Germany, Honduras, Poland, Spain, United Kingdom
Outcome results
None listed